Abstract:Although multiple studies have confirmed the value of thoracic radiation therapy (RT) in limited-stage small-cell lung cancer (LS-SCLC), the appropriate RT dose remains controversial. This study aimed to evaluate the correlation between the biologically effective RT dose and local tumor control and overall survival for patients with LS-SCLC. The medical records of 205 LS-SCLC patients treated with radical RT (≥50 Gy) and combined chemotherapy at the Fudan University Cancer Hospital between 1997 and 2006 were retrospectively reviewed. Biologically effective dose (BED) was calculated for RT dose homogenization. Patients were grouped by BED (≤57 Gy and >57 Gy, 57 Gy equivalent to 60 Gy in 30 fractions in 6 weeks). Treatment interruption during RT was used as the “marker” for treatment toxicity. Kaplan-Meier analysis was used to calculate overall survival (OS), progression-free survival (PFS), local control rate (LCR), and distant-metastasis-free survival (DMFS) for both groups of patients. Of the 205 patients, 70 had received ≤57 Gy (lower BED group) and 135 >57 Gy (higher BED group). The patient and treatment characteristics were similar in the two groups except for the daily fractions, twice-daily RT was significantly more frequent in the higher BED group (p = 0.000). RT interruptions were recorded in 46 cases (22%), with a median duration of 6 days (range, 1-18). No differences in treatment-related toxicity rates were demonstrated between the two BED groups (p = 0.339).The median follow-up time was 20.7 months (range, 3.6-102.8 months) for all analyzable patients and 50.8 months (range, 27.3-102.8 months) for patients alive. The LCR and DMFS at 2 years for the higher and lower BED groups were 83.7% and 62.5% (p = 0.024) and 55.7% and 43.0% (p = 0.196), respectively. Patients in the higher BED group had a statistically significant better 5 years OS (26.2% vs. 14.6%, p = 0.005) and PFS (19.4% vs. 12.9%, p = 0.006). There were no significant difference for OS between the once-daily and twice-daily groups (p = 0.575). Multivariable Cox regression model demonstrated that age (p = 0.004), Karnofsky performance status (p = 0.005), weight loss < 5% (p = 0.032), and BED (p = 0.043) were significant predictors of OS. This study has shown that patients treated with BED > 57 Gy have better LCR, PFS and OS compared those treated with BED ≤ 57 Gy, indicating that a positive BED-response relationship still exist even though in a scope of relatively high BED. Future studies are warranted to examine the optimal RT doses and fractionation to achieve the appropriate BED for LS-SCLC, especially with modern RT techniques.

Radiotherapy with Low Dose Per Fraction Reduces Probability of Long-Term Normal Tissue Complications While Providing a Satisfactory Tumor Local Control in Non-Hodgkin Lymphoma

Is it necessary to prescribe the same dose to subclinical lesions as gross tumor volume in non-small-cell lung cancer? —a failure pattern analysis

Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma?

Low radiotherapy dose is suitable for brain metastases in SCLC compared with high dose

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma

Radiation Dose Reduction for Patients with Extranodal NK/T-cell Lymphoma with Complete Response after Initial Induction Chemotherapy

Short-term efficacy and long-term survival of limited-stage small cell lung cancer treated with large fractionation radiotherapy and conventional fractionation radiotherapy.

Radiation-Induced Lymphopenia is Associated with Radiation Fractionation and Predicts Poorer Prognosis in Patients with Breast Cancer

Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma.

Effective radiotherapy dose for suspicious positive cervical lymph nodes for N 0 nasopharyngeal carcinoma patients : a prospective cohort study

Late Effects of Modern Therapy for Hodgkin Lymphoma

Hypofractionated Stereotactic Radiation Therapy for Advanced Non-Small Cell Lung Cancer: Report on Clinical Outcome and Toxicity

Multicenter phase II study of moderate low-dose radiotherapy in indolent non-Hodgkin lymphoma: CLCG-iNHL-01 protocol

Efficiency of moderately hypofractionated radiotherapy in NSCLC cell model

Long-term Results of High-Dose Conformal Radiotherapy for Patients with Medically Inoperable T1-3N0 Non-Small-cell Lung Cancer: is Low Incidence of Regional Failure Due to Incidental Nodal Irradiation?

Reducing Target Volumes of Intensity-Modulated Radiotherapy Following Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Biologically Effective Dose-response Relationship for Patients with Limited-stage Small-cell Lung Cancer Treated with Combined Radiotherapy and Chemotherapy

An Analysis of Local Advanced Non-small Cell Lung Cancer Treated with Image-guided Hypofractionated Intensity Modulated Radiotherapy combined with Chemotherapy

A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma

Impact of Minimum Point Dose on Local Control and Toxicity in T3–4 Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy Plus Chemotherapy